How should an asymptomatic patient with elevated hemoglobin and hematocrit be evaluated?

Evaluation of Asymptomatic Elevated Hemoglobin and Hematocrit

Begin by confirming true erythrocytosis with repeat hemoglobin and hematocrit measurements, then immediately order JAK2 mutation testing alongside a complete blood count with differential, serum ferritin, transferrin saturation, and erythropoietin level to distinguish polycythemia vera from secondary causes. 1, 2

Initial Confirmation and Laboratory Workup

Use hemoglobin rather than hematocrit for diagnosis and monitoring because hemoglobin remains stable during sample storage while hematocrit can falsely increase by 2-4% with prolonged storage, and hyperglycemia can falsely elevate hematocrit without affecting hemoglobin. 1

Diagnostic Thresholds for True Erythrocytosis

• Men: Hemoglobin >18.5 g/dL or hematocrit >55% 1, 2
• Women: Hemoglobin >16.5 g/dL or hematocrit >49.5% 1, 2

Essential First-Line Tests

• Complete blood count with red cell indices (MCV, MCH, MCHC, RDW) to assess all cell lines and detect concurrent abnormalities 1, 2
• JAK2 mutation testing (both exon 14 V617F and exon 12) as the cornerstone diagnostic test—positive in up to 97% of polycythemia vera cases 1, 3
• Serum ferritin and transferrin saturation to identify coexisting iron deficiency, which commonly occurs with erythrocytosis and causes microcytic polycythemia 1, 2
• Reticulocyte count to evaluate bone marrow response 1
• Serum erythropoietin level to differentiate primary (low/normal) from secondary (elevated) causes 1
• C-reactive protein as part of the minimum workup 1
• Peripheral blood smear review by a qualified hematologist to assess cell morphology and rule out myeloproliferative disorders 2, 3

Distinguishing Polycythemia Vera from Secondary Causes

WHO Diagnostic Criteria for Polycythemia Vera

Diagnosis requires EITHER:

1. Both major criteria (elevated hemoglobin/hematocrit AND JAK2 mutation) plus one minor criterion, OR
2. First major criterion plus two minor criteria 1, 3

Major Criteria:

• Hemoglobin >16.5 g/dL (women) or >18.5 g/dL (men), OR hematocrit >48% (women) or >49% (men) 1
• Presence of JAK2 mutation 1, 3

Minor Criteria:

• Bone marrow hypercellularity with trilineage myeloproliferation 1, 3
• Subnormal serum erythropoietin level 1, 3
• Endogenous erythroid colony formation in vitro 1, 3

Systematic Evaluation for Secondary Causes

If JAK2 mutation is negative, systematically evaluate secondary causes:

Hypoxic causes:

• Smoking history and carbon monoxide exposure—"smoker's polycythemia" resolves with cessation 1, 3
• Sleep study if obstructive sleep apnea suspected (nocturnal hypoxemia drives erythropoietin production) 1, 3
• Pulmonary function tests and chest imaging for chronic obstructive pulmonary disease 1, 3
• Altitude of residence—physiologic adaptation increases hemoglobin by 0.2-4.5 g/dL depending on elevation (1,000-4,500 meters) 1

Non-hypoxic causes:

• Testosterone use (prescribed or unprescribed)—common cause in young adults requiring dose adjustment or discontinuation 1, 3
• Renal imaging (ultrasound or CT) to exclude renal cell carcinoma, hydronephrosis, or cystic disease producing erythropoietin 1
• Review for other erythropoietin-producing tumors (hepatocellular carcinoma, pheochromocytoma, uterine leiomyoma, meningioma) 1

Relative polycythemia (plasma volume depletion):

• Assess hydration status by reviewing fluid intake and recent losses—dehydration is the most common cause 3
• Review diuretic use which can cause plasma volume depletion 3

Critical Pitfalls to Avoid

• Do not assume dehydration without clinical confirmation—a near-normal hemoglobin may actually represent dehydration masking anemia 3
• Do not overlook coexisting iron deficiency—iron-deficient red cells have reduced oxygen-carrying capacity and deformability, paradoxically increasing stroke risk despite elevated hemoglobin 1, 3
• Mean corpuscular volume is unreliable for screening iron deficiency in erythrocytosis—serum ferritin and transferrin saturation are required 1
• Do not perform routine or repeated phlebotomies without clear indication—this causes iron depletion, decreased oxygen-carrying capacity, and paradoxically increases stroke risk 1

Management Based on Diagnosis

For Confirmed Polycythemia Vera

• Maintain hematocrit strictly below 45% through therapeutic phlebotomy to reduce thrombotic risk (CYTO-PV trial showed 2.7% vs 9.8% thrombotic event rate, P=0.007) 1, 2
• Initiate low-dose aspirin (81-100 mg daily) as second cornerstone of therapy for thrombosis prevention 1, 2
• Immediate hematology referral for ongoing management 3

For Secondary Erythrocytosis

• Treat the underlying condition:

  • Smoking cessation for smoker's polycythemia 1, 3
  • CPAP therapy for obstructive sleep apnea 1
  • Management of chronic lung disease 1
  • Testosterone dose adjustment or discontinuation 1, 3

• Therapeutic phlebotomy is indicated ONLY when ALL of the following are met:

  • Hemoglobin >20 g/dL AND hematocrit >65% 1, 3
  • Documented symptoms of hyperviscosity (headache, visual disturbances, dizziness) 1, 3
  • Dehydration has been excluded 1, 3
  • Iron deficiency has been excluded (transferrin saturation ≥20%) 1

• When phlebotomy is performed, replace with equal volume of fluid to prevent hemoconcentration and reduce stroke risk 1

Iron Management in Erythrocytosis

• If transferrin saturation <20%, initiate cautious oral iron supplementation with close hemoglobin monitoring rather than phlebotomy 1
• Avoid iron deficiency even in the presence of erythrocytosis—iron-deficient red cells increase stroke risk 1

Immediate Referral Indications

• Positive JAK2 mutation requires immediate hematology referral 3
• Hemoglobin >20 g/dL with symptoms of hyperviscosity requires urgent hematology consultation 3
• Unexplained splenomegaly with elevated blood counts mandates hematology evaluation 3
• Diagnosis remains unclear after initial workup warrants hematology referral 1

Monitoring Strategy

• For borderline values, repeat measurements to confirm persistent elevation rather than transient changes 1
• Serial measurements every 6-12 months for asymptomatic JAK2-negative erythrocytosis with hematocrit <65% 1
• Use hemoglobin for ongoing monitoring rather than hematocrit due to superior stability and accuracy 1, 2